US Pharma MarketingMakary's ouster would create another high-profile vacancy atop RFK Jr.'s health department. FDA research global health Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on…
President Trump has reportedly signed off on a plan to dismiss Food and Drug Administration Commissioner Marty Makary. It would be the latest high-profile departure to hit Robert F. Kennedy Jr.’s health department.
Makary has served in the role for a little over a year. His tenure was ambitious, filled with the announcements of dozens of new initiatives, including efforts to shorten drug review timelines, crack down on misleading ads, and pressure the food industry to remove chemical dyes.
Source: STAT News Pharma